Drugs / PRG2505
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRG2505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07307053 ↗ |
| Known as | V001 Injection | “PRG2505 (developmental code: V001 Injection)” NCT07307053 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T-cell (CAR-T) therapy” NCT07307053 ↗ |